The well-recognized "big" forms (45,000-100,000 mol wt) of immunoreactive human growth hormone (hGH) in human serum have been reported to be random aggregates or formal polymers. However, we have now investigated the possibility that they are protein-bound forms. After incubation of monomeric 125I-hGH with normal serum, gel chromatography indicated a peak of bound 125I-hGH (at approximately 120,000 mol wt), which was completely displaced by excess unlabeled hGH. When serum alone was chromatographed two peaks of specific binding were subsequently detected, the major peak, eluting between 74,000 and 85,000 mol wt corresponded to the 125I-hGH-binding protein complex observed at approximately 120,000 mol wt. Using a mini-gel filtration system for separating bound from free hormone, binding of 125I-hGH by normal human serum was dependent on time (equilibrium was reached in 2 h at 21 degrees C), temperature (21 degrees C greater than 37 degrees C), Ca2+ and serum concentrations. Binding was reversible and highly specific for hGH, not being displayed by GH or prolactins from several species. Scatchard analysis revealed linear plots with an affinity (KA) of 0.32 +/-0.06 X 10(9) M-1 (n = 7). Human serum with low endogenous hGH levels, when added to rabbit liver membranes, decreased the binding of 125I-hGH in this tissue in a dose-dependent manner. These data indicate that human sera contain a specific, high affinity 
Introduction
It has been recognized for more than a decade that there is considerable size and charge heterogeneity ofgrowth hormone (GH)' in human serum (for reviews see [1] [2] [3] . Marked discrepancies have also been reported in both rat and human sera between radioimmunoassayable GH activity and growth-promoting bioactivity (4) , although no discrepancy was observed for metabolic (5) or lactogenic bioactivities (6) . These observations raise the possibility that forms of GH with altered activity (e.g., reduced immunoactivity or enhanced bioactivity) may be involved in, and important for, the overall growth promoting activity of serum. These aspects ofthe chemical nature and activity ofGH, or GH-like molecules, are still poorly understood.
Several groups (7) (8) (9) (10) (11) (12) (13) (14) have shown that gel chromatography of human serum, or human pituitary extracts, yields three major immunoreactive species ofhGH-little or monomeric GH (22,000 mol wt), big GH (-45,000 mol wt) and big-big GH (variable but »60,000 mol wt). Little GH has been shown more recently to exist in several forms-the 22,000-mol wt single chain major form, the 20,000-mol wt variant, and probably three proteolytically cleaved two-chain forms (1) . The 20 ,000-mol wt form is considered to have normal growth promoting activity but diminished insulinlike metabolic activity (3) . Some (15, 16) , but not all reports (17) , suggest that the two-chain forms may have enhanced biological activity. In contrast, several of the studies (1 1-14) of the big and big-big forms reported a diminished activity in radioreceptor assays relative to immunoassays, thus leading to the suggestion that the larger forms may be less biologically active.
Overall, the chemical nature ofthese larger forms ofGH has been controversial. The possibilities considered were that they represented hGH precursors, hGH aggregates (either random or formal polymers, including disulfide-linked forms), hGH bound to one or more serum proteins or immunoassay artifacts. The most widely held view has been that they are hGH aggregates and this was recently supported by a detailed investigation by Stolar et al. (18) who deduced that big GH was an hGH dimer and big-big GH was a mixture of tri-, tetra-, and pentamers. Although it appeared that unlabeled hGH, when incubated with plasma (1 h, 22°C) did not appreciably change its molecular size (as determined by radioimmunoassay of fractions from Sephadex G-100 gel filtration), close inspection of their data indicates that one cannot rule out the possibility that GH binding to one or more plasma proteins, as opposed to simple aggregation, would be a sufficient and satisfactory explanation for the size heterogeneity.
This possibility is supported by the recent demonstration in this laboratory of an abundant, high affinity, and specific GHbinding protein in the sera of normal and pregnant rabbits (19 (19, 20) . When 1 2 5 IhGH-serum complexes (250 Al; 20,000 cpm) were gel filtered the elution profile of serum GH binding proteins was determined by simply counting the radioactivity of each fraction. When serum alone (0.6 ml) was chromatographed the GH binding profile was determined by taking100-,ul aliquots from each l-ml column fraction, incubating with'25I-hGH for 2 hand then measuring specific binding by separation of bound and free GH on AcA44 mini-columns. The AcA34 column was calibrated with blue dextran (JV.), riboflavin (Vt), and molecular weight markers as listed previously (19) .
Results
Incubation of normal human serum (2 h, 21°C) with'251-hGH followed by gel chromatography on Ultrogel AcA34 gave rise to three peaks of radioactivity (Fig. 1 a) . Peak 1, eluting at a position corresponding to 120,000 mol wt was not present when excess unlabeled hGH was included in the incubation and therefore represents a specifically bound peak of1251I-hGH. This peak was not symmetrical, having a shoulder (which was also displaceable by unlabeled hGH), tailing into peak 2, the largest peak that represents unbound 125I-hGH. Peak 3 appeared at the total volume of the column and represents free iodine or low molecular weight degradation products.
In contrast, two peaks of specific binding were observed after incubation of 125I-hGH with individual column fractions ob- tained from gel filtration of serum alone ( Fig. 1 b) . The major peak, eluting at 74,000-85,000 mol wt, was broad but corresponded in principle with the position one would expect for a binding protein that formed an -120,000-mol wt complex with hGH ( Fig. 1 a) . Rather surprisingly, a second peak of binding activity was detected near the void volume of the column (>400,000 mol wt); this peak was never seen after gel filtration of 1251-hGH-serum incubation mixtures (as in Fig.1 a) . We currently have no adequate explanation for this anomaly unless formation of this high molecular weight species is prevented in whole serum by the presence of the more abundant lower molecular weight binding species. Attempts to determine the affinity of this high molecular weight binding protein by Scatchard analysis have been relatively unsuccessful due to poor reproducibility and an apparent lability of this binding species (not shown).
Since this form is not detected by incubations of '251-hGH with whole serum (Fig.1 a) it has been assumed in the subsequent experiments reported, that binding characteristics of the lower molecular weight (-120,000) 125I-hGH-binding protein complex only were being analyzed.
In a similar manner to that described previously for rabbit tissue cytosols (20, 24) and serum (19) , the GH binding activity of human serum was not detectable using a 12.5% (wt/wt) final concentration of polyethylene glycol 6000 or a dextran-charcoal separation system (data not shown). For this reason the AcA44 mini-column system (19) was used to further characterize the GH binding protein of normal human serum.
In addition to the demonstration of serum binding of 251-labeled hGH, incubation of serum with unlabeled, monomeric (22,000 mol wt) hGH led to a prominent shift in the radioimmunoassayable GH profile into a higher molecular weight gel filtration fraction (Table I) . hGH alone, when chromatographed (19) . GH binding protein is known to elute primarily in fraction 2; monomeric hGH is known to elute in fractions 4 and 5. Each column fraction was dialyzed, lyophilized, and measured in duplicate for hGH content by a standard hGH radioimmunoassay. The hGH content of each fraction is given as a percentage of total hGH recovered; very similar data were obtained in a second experiment.
on Ultrogel AcA44 mini-columns eluted in fractions 4 and 5, whereas after incubation with serum (or with hGH-Affigel affinity-purified binding protein2) a small but unambiguous proportion eluted in fraction 1-3. The proportion of unlabeled hGH measured in fraction 2 is slightly overestimated since the binding protein itself, which is known to elute in this same fraction on mini-columns (see ref. 19 ), can be partially detected as an apparent GH peak by GH radioimmunoassay due to sequestration of 125I-hGH tracer. However, the data of Fig. 2 b) . The mean level of binding at equilibrium for 50 Ml normal human serum was 8.0±0.5% (mean±SEM, n = 7). Binding at physiological temperature was somewhat lower but tended to reach equilibrium more rapidly. The binding of '251-hGH was rapidly reversible (as shown in Fig. 2 b) with a half-time for dissociation of 27-44 min. There was no evidence for any tracer degradation at either temperature, as determined by trichloracetic acid precipitation of the incubation medium. Fig. 3 a shows the dependence of specific binding on the amount of serum used with binding being linear up to 100 Ml (in 250 Ml total volume) and being detectable with as little as 6 Ml. Fig. 3 b indicates that, unlike tissue GH binding proteins in other species (25-27), there was only a minor effect ofCa2+ on hGH binding, which increased in a linear manner (by up to 44%) as the Ca2+ concentration rose from a physiological level (2.5 mM) up to 40 mM.
The hormonal specificity of binding of '25I-hGH by human serum is shown in Fig. 4 Scatchard analysis ofdata obtained from a classical displacement curve (Fig. 5 a) yielded linear plots (Fig. 5 b) . The mean (±SEM) binding parameters calculated for seven determinations on four different normal human sera (including one pool of >50 different normal samples) were: affinity (KA) 0.32±0.06 X 109 M-', capacity 26.5±4.5 fmol/mg serum protein or 1841±320 fmol/ml serum. Specific binding of hGH has been detected in all 39 human sera so far examined (Fig. 6 ). These sera were obtained from 29 different subjects with varying levels of radioimmunoassayable hGH (GH-deficient, normal, acromegalic). A weak negative linear correlation (r = -0.526) was observed between GH binding and GH content of these sera (Fig. 6) (7, 8, 18) . In our studies, a mini-gel filtration system ald not be ac-(Ultrogel AcA44, 0.6 X 22 cm) has been used to achieve an ,erum (<2 ng/ appropriately rapid, simple, quantitative, and discriminatory ).005) in three separation. This system was devised originally for quantitative uch inhibition measurement of soluble GH binding proteins in rabbit serum nbranes, dem- (19) and tissue cytosols (24) . hGH binding
The levels of binding protein detected in normal human serum are quite significant, particularly considering that presumably only unoccupied binding protein would be measured under the conditions of incubation. That some binding protein is occupied by endogenous hormone is suggested by the inverse correlation between binding protein and circulating GH levels. ntain a highly Indeed, the calculated binding capacity of normal sera (-1,800 igh affinity fior fimol/ml serum), which would be underestimated given the likeird to one-fifth lihood of endogenous occupancy, would be sufficient to bind all (28) liver (29), of the GH present in normal serum (-500-i,000 fmol/ml).
)th '251-labeled However, if one also accounts for the binding affinity (KA 0.3 ile serum bind-X 109 M-1), then at 500 fmol GH/ml the binding protein would this is the first be -10% occupied. On the basis of a 1:1 binding stoichiometry ,teristics of the between GH and its binding protein, one can then estimate that kown that OH in normal sera -30-40% of GH may be in a bound form. This serum concenhbinding compares with values for the percent big-big (i.e., >60,000 mol e n hg wt and presumed aggregated) GH forms reported by others: 13-nl using hwH-36% (13), >50% (37) with 60,000-100,000 mol wt, include protein-bound forms rather than just aggregated/polymeric forms. The concept of binding proteins in serum is not new for hormones such as steroids and thyroid hormones, nor for the polypeptide growth factors, insulinlike growth factors (43), platelet (44) , epidermal, and nerve growth factors (45) .
Although not yet a recognized phenomenon for larger polypeptide hormones such as GH, in fact there are, apart from our earlier study in rabbit serum (19) , several references in the older literature (31) (32) (33) (34) (35) (36) (37) (38) The physiological role of such a binding protein is not yet clear, however, given that more than half of the hGH remains in the free or monomeric state. Several possibilities are worth considering. First, the binding protein may have a protective effect against very high levels of hGH; it is well-recognized that the big forms of hGH reported previously are less biologically active (1 1-14) . Dwarfism due to an increase in the presence of big and big-big hGH forms has been reported (46) . Such a role for big GH, however, would not appear to explain the dichotomy between hGH levels and clinical symptoms in acromegaly since the dichotomy remains if one measures only the monomeric form (42) . Second, the binding protein may be designed to maintain a steady baseline of GH in the face of the pulsatile secretion from the pituitary: it has been shown recently (47) that the larger forms of hGH are cleared more slowly from the circulation. Third, it may be that bound forms ofhGH are protected from degradation or alternatively are preferred for the in vivo generation of various biologically active GH fragments (3). A further consequence ofthe presence of unoccupied GH binding protein in serum may be a significant effect on the receptor-and immunoassayable levels of GH; the binding protein, via competition for the labeled ligand, leading to an overestimation of hGH. This would be analogous to the situation with the mea- Finally, we know nothing as yet regarding the origin of the binding protein. One possibility is that like GH itself it is secreted from the pituitary gland since it is known that higher molecular weight forms of GH are present in pituitary extracts (7, 1 1). A possibility considered more likely, however, is that it is secreted by or shed from the liver and other GH target tissues. This suggestion is based on the very close antigenic and structural relationship between the rabbit liver membrane GH receptor, the rabbit serum GH binding protein (19) , and a GH binding protein found in target tissue high-speed cytosol preparations (24) . of normal human serum on the specific binding of '25I-hGH to pregnant female rabbit liver membranes. Binding was carried out at room temperature for 2 h with a final membrane protein concentration of 400 Mg/ml as described previously (14) , but in the presence or absence of human serum. Each histogram is the mean of duplicate determinations that differed by <6% in all cases. Data from three such experiments that have been carried out indicated that the effect of serum was significant (Student's t test) at serum levels of 50 Ml (P < 0.05), 100 il (P < 0.01), and 150 Ml (P < 0.005). 
